Thursday, July 17, 2014
Publication and contact
Neuromedin U (NMU);
Cell culture and mouse
studies suggest inhibiting NMU could help treat HER2 inhibitor-resistant
breast cancer. In human breast cancer cells, elevated NMU levels were
associated with poor clinical outcomes and resistance to HER2 inhibitors. In
HER2+ human breast cancer cell lines treated with a HER2
inhibitor, NMU-targeting siRNA decreased proliferation and invasiveness
compared with scrambled siRNA. In mice injected with a human breast cancer
cell line resistant to Tykerb
pretreatment of cells with NMU-targeting shRNA decreased tumor growth and
metastases and increased survival compared with no pretreatment. Future
studies could include identifying and testing pharmacological NMU inhibitors
in HER2 inhibitor-resistant cancers.
plc and Eddingpharm
Inc. market Tykerb lapatinib, an inhibitor of epidermal
growth factor receptor 1 (EGFR1;
and HER2, to treat breast cancer. The drug is in Phase III testing to treat
head and neck cancer and gastric cancer and Phase II trials to treat brain
and liver cancers.
and its Genentech
Inc. and Chugai
Pharmaceutical Co. Ltd. units market Herceptin
a humanized mAb against HER2, to treat breast and gastric cancers.
Ingelheim GmbH markets Gilotrif
a dual inhibitor of HER1 and HER2, to treat non-small cell lung cancer
(NSCLC). The drug is in Phase III testing to treat breast cancer and head and
neck cancer and Phase I trials to treat solid tumors.
Published online July 17, 2014
Patent and licensing status
S. et al. Cancer Res.;
published online May 29, 2014;
Contact: Lorraine O'Driscoll, Trinity College Dublin, Dublin, Ireland
All contents Copyright © 1993-2017 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]